Search

Your search keyword '"Balleine, Rosemary"' showing total 307 results

Search Constraints

Start Over You searched for: Author "Balleine, Rosemary" Remove constraint Author: "Balleine, Rosemary"
307 results on '"Balleine, Rosemary"'

Search Results

1. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival

2. Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum

3. The impact of coding germline variants on contralateral breast cancer risk and survival

5. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

6. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.

7. Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

8. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset

10. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.

11. Strategies to enable large-scale proteomics for reproducible research

13. Older age should not be a barrier to testing for somatic variants in homologous recombination DNA repair-related genes in patients with high-grade serous ovarian carcinoma

14. Supplemental figure 1 legend from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

15. Data from Poor-Prognosis Estrogen Receptor–Positive Breast Cancer Identified by Histopathologic Subclassification

16. Supplemental figure 1 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

17. Supplementary Figure S1 from Poor-Prognosis Estrogen Receptor–Positive Breast Cancer Identified by Histopathologic Subclassification

18. Supplemental table S3 from Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study

19. Supplementary Methods, Figures 1-5 from Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver

20. Supplementary Highlighted Methods from Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver

22. Supplementary Tables 1-7 from Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and TP53-Mutant Tumors and Identifies NRAS as an Oncogenic Driver

23. Data from Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

24. Supplementary Materials and Methods, Tables 1-5 from Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer

26. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

29. Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants

30. Identification of Novel Genetic Markers of Breast Cancer Survival

33. CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers

40. Genome-wide association study identifies novel breast cancer susceptibility loci

41. Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes

43. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk

Catalog

Books, media, physical & digital resources